Akari Therapeutics ADR (AKTX) Stock Price, Quote & News

Company Profile

Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads in...

Industry: Biotechnology

Sector: Healthcare

Phone: 929 274 7510

Fax: 929 274 7553

Website: www.akaritx.com

Address:

22 Boston Wharf Road, Floor 7, Boston, United States

jennybaby Aug. 6 at 4:14 PM

$AKTX never fails to disappoint 🤯🤯🤯🤯🤯

0 · Reply

Radek93 Aug. 4 at 2:58 PM

$AKTX

0 · Reply

MTN Jul. 31 at 1:52 AM

$AKTX as usual, low volume takedown. Getting tired of the same bs.

0 · Reply

StockTwitsNinja Jul. 30 at 3:53 PM

$AKTX Another round of dilution coming. SIGH!

1 · Reply

718Pigeon Jul. 30 at 2:37 PM

$AKTX

0 · Reply

stockscan Jul. 29 at 1:29 PM

$AKTX new video https://investor.akaritx.com/news-releases/news-release-details/akari-therapeutics-releases-virtual-investor-what-means-0

0 · Reply

dan16 Jul. 28 at 5:58 PM

$AKTX Waiting for a 100K volume day. Then another one. Then I will start getting excited.

0 · Reply

MTN Jul. 27 at 10:15 PM

$AKTX https://www.wsj.com/finance/currencies/crypto-treasury-e7ae573c?st=5EFRbh Aktx should just announce a crypto fund for their pharma research and watch this skyrocket. Stupid money going into crypto now.

0 · Reply

stockscan Jul. 23 at 1:24 PM

$AKTX https://investor.akaritx.com/news-releases/news-release-details/akari-therapeutics-continues-key-research-its-novel-antibody

1 · Reply

FinJay Jul. 23 at 3:07 AM

$AKTX https://youtu.be/xTc7pW0ZXKI

0 · Reply

Akari Therapeutics Releases Virtual Investor “What This Means” Segment

Jul 23, 2025, 8:55 AM EDT - 14 days ago

Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers

Jul 22, 2025, 8:45 AM EDT - 15 days ago

Akari Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jun 25, 2025, 9:00 AM EDT - 6 weeks ago

Akari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its Recently Granted India Patent

Jun 18, 2025, 8:50 AM EDT - 7 weeks ago

Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India

May 29, 2025, 9:15 AM EDT - 2 months ago

Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology

May 22, 2025, 9:00 AM EDT - 2 months ago

Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

May 19, 2025, 8:00 AM EDT - 2 months ago

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

CRBP QURE

May 15, 2025, 8:05 AM EDT - 2 months ago

Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 1, 2025, 8:45 AM EDT - 3 months ago

Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology

Apr 22, 2025, 9:05 AM EDT - 3 months ago

Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala

Mar 20, 2025, 8:35 AM EDT - 4 months ago

Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer

Mar 3, 2025, 9:00 AM EST - 5 months ago

Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules

Feb 19, 2025, 9:00 AM EST - 6 months ago

Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 3, 2025, 8:00 AM EST - 6 months ago

Akari Therapeutics Joins Webull Corporate Connect Service Platform

Dec 18, 2024, 8:51 AM EST - 8 months ago

Akari Therapeutics Announces Key Leadership Appointments

Dec 16, 2024, 9:05 AM EST - 8 months ago

Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer

Nov 14, 2024, 4:15 PM EST - 9 months ago

Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio

Nov 8, 2024, 8:00 AM EST - 9 months ago

Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger

Aug 19, 2024, 4:15 PM EDT - 1 year ago

Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights

Aug 19, 2024, 8:00 AM EDT - 1 year ago

Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy

May 16, 2024, 8:00 AM EDT - 1 year ago

Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights

May 1, 2024, 8:01 AM EDT - 1 year ago

Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics

May 1, 2024, 8:00 AM EDT - 1 year ago

Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity

Apr 15, 2024, 8:00 AM EDT - 1 year ago

Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024

Apr 1, 2024, 6:30 AM EDT - 1 year ago

Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights

Mar 5, 2024, 8:00 AM EST - 1 year ago

Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit

Jan 2, 2024, 8:00 AM EST - 1 year ago

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing

Dec 14, 2023, 8:00 AM EST - 1 year ago

Akari Therapeutics to Present at Biotech Showcase 2024

Dec 1, 2023, 8:00 AM EST - 1 year ago

Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D.

Nov 16, 2023, 8:00 AM EST - 1 year ago

Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

Nov 6, 2023, 8:00 AM EST - 1 year ago

Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

Sep 29, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Reports First Half 2023 Financial Results and Highlights

Sep 27, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics to Present at Emerging Growth Conference

Sep 21, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit

Sep 19, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Aug 18, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials

Aug 15, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics, Plc Announces ADS Ratio Change

Aug 2, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs

Jul 27, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Granted Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation

Jul 19, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Appoints Experienced Life Sciences Executive Wendy DiCicco as Interim Chief Financial Officer

Jul 13, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA

Jul 11, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy

Jul 6, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Nomacopan for Treatment in Hematopoietic Stem Cell Transplantation

Jul 5, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Appoints Industry Veteran Wa'el Hashad to Board of Directors

May 16, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics to Participate in A.G.P.'s Virtual Healthcare Conference

May 1, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Reports Full-Year 2022 Financial Results and Highlights

Apr 25, 2023, 4:15 PM EDT - 2 years ago

Akari Therapeutics Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirement

jennybaby Aug. 6 at 4:14 PM

$AKTX never fails to disappoint 🤯🤯🤯🤯🤯

0 · Reply

Radek93 Aug. 4 at 2:58 PM

$AKTX

0 · Reply

MTN Jul. 31 at 1:52 AM

$AKTX as usual, low volume takedown. Getting tired of the same bs.

0 · Reply

StockTwitsNinja Jul. 30 at 3:53 PM

$AKTX Another round of dilution coming. SIGH!

1 · Reply

718Pigeon Jul. 30 at 2:37 PM

$AKTX

0 · Reply

stockscan Jul. 29 at 1:29 PM

$AKTX new video https://investor.akaritx.com/news-releases/news-release-details/akari-therapeutics-releases-virtual-investor-what-means-0

0 · Reply

dan16 Jul. 28 at 5:58 PM

$AKTX Waiting for a 100K volume day. Then another one. Then I will start getting excited.

0 · Reply

MTN Jul. 27 at 10:15 PM

0 · Reply

stockscan Jul. 23 at 1:24 PM

$AKTX https://investor.akaritx.com/news-releases/news-release-details/akari-therapeutics-continues-key-research-its-novel-antibody

1 · Reply

FinJay Jul. 23 at 3:07 AM

$AKTX https://youtu.be/xTc7pW0ZXKI

0 · Reply

stockscan Jul. 22 at 1:42 PM

$AKTX https://investor.akaritx.com/news-releases/news-release-details/akari-therapeutics-participates-virtual-investor-whats-your Everytime i hear the new ceo, i am feeling more confident in his leadership.. hope he can bring long-term shareholder value 🙏

1 · Reply

MTN Jul. 19 at 8:23 PM

$AKTX https://www.investing.com/news/analyst-ratings/maxim-group-initiates-coverage-on-akari-therapeutics-stock-with-buy-rating-93CH-4141856

0 · Reply

stockscan Jul. 18 at 4:48 PM

$AKTX https://webull.zoom.us/rec/play/_a4EkGbVPv2UtiNF42ZLVMgzBCSiEg7Q_wiXdZPRIF6i8ttsccta9nv48vtzjCJ3dCWIqqnnM2oVvBUO.sS8SC0_xaK1jGW63 This was given by the CEO after a month since joining, and i liked the way he differentiated AKTX approach to ADC.

1 · Reply

JarvisFlow Jul. 18 at 4:28 PM

Maxim Group has adjusted their stance on Akari Therapeutics ( $AKTX ), setting the rating to Buy with a target price of 5.

1 · Reply

StockTwitsNinja Jul. 15 at 3:17 PM

$AKTX Slow bleed every single day and it will go below 1 when stock market is at all time high. No update from new CEO. I imagine, who would they hire next year

0 · Reply

MTN Jul. 11 at 4:20 AM

$AKTX https://virtualinvestorco.com/aktx/

0 · Reply

MTN Jul. 11 at 4:20 AM

$AKTX https://akaritx.com/2025/06/25/akari-therapeutics-releases-virtual-investor-what-this-means-segment-highlighting-its-recentlygranted-india-patent/

0 · Reply

StockTwitsNinja Jul. 9 at 5:05 PM

$AKTX Is this the worst performing stock ever or is it just auditioning for the part? Do we still have any brave investors hanging on or has everyone already jumped ship?

2 · Reply

dan16 Jun. 23 at 2:07 AM

$AKTX Looks like our new CEO got 246,428 shares as part of his coming on board. At least that's how I read it. But he did just buy 15,000 shares. Not a lot, but sill positive. https://www.nasdaq.com/market-activity/stocks/aktx/insider-activity

0 · Reply

Radek93 Jun. 10 at 6:55 PM

$AKTX

0 · Reply

StockTwitsNinja Jun. 4 at 4:38 PM

$AKTX Why did I invest in this shit. WHY

0 · Reply

PSM_EmpowerTrading May. 28 at 7:18 PM

⌛️⏳️ Potential swing ideas 💡 ✅️ $AKTX company specializing in the development of next-generation precision bi-functional antibody-drug conjugates (ADCs) for cancer treatment, lead candidate, AKTX-101, upcoming catalysts: 1) preclinical data presentation 2nd half 2025, 2) expanding preclinical studies to explore AKTX,101's's efficacy in various solid tumor indications, including prostate and lung cancers, 3) company exploring research collaborations, 4) participating in ASCO Annual Meeting from May 30 to June 3 in Chicago, 4) Live webinar on $BULL this Thursday 5/29 pm EST to discuss pipelines and upcoming catalysts ✅️ $SONM small float, recently announced new products set to launch in North America, EMEA, and Australia, 3 products in Q2 in North America, company is a leading US provider of rugged mobile solutions 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D

0 · Reply

Market Cap	33.14M
Revenue (ttm)	0.00
Net Income (ttm)	-19.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.03

Volume	31,140
Avg Vol	25,366
Day's Range	N/A - N/A
Shares Out	32.18M
Stochastic %K	15%
Beta	0.22
Analysts	Strong Sell
Price Target	$6.00